[Home ] [Archive]   [ فارسی ]  
:: Main :: About us :: Current Issue :: Archive :: Search :: Submit :: Contact ::
:: Volume 18, Issue 3 (Autumn 2021) ::
Sci J Iran Blood Transfus Organ 2021, 18(3): 187-195 Back to browse issues page
Evaluation of alloantibodies in thalassemia patients referred to Hamadan Besat hospital in 2019
M. Afshari, F. Amiri , M.R. Seyedi, M. Biglari, H. Jambozorg
Keywords: Thalassemia, Blood Transfusion, Screening
Full-Text [PDF 478 kb]   (99 Downloads)     |   Abstract (HTML)  (294 Views)
Type of Study: Research | Subject: Blood Transfusion
Published: 2021/10/2
Full-Text:   (115 Views)
References:
  1. Vafaei M, Azad M, Shiargar P, Kazemi Haki B. Quality of life in patients with thalassemia major referred to Ardabil Buali Hospital in 2012-13. medical sciences  2015; 25(4): 305-10. [Article in Farsi]
  2. Rachmilewitz EA, Giardina PJ. How I treat thalassemia. Blood. 2011;118(13):3479-88.
  3. Seferi I, Xhetani M, Face M, Burazeri G, Nastas E, Vyshka G. Frequency and specificity of red cell antibodies in thalassemia patients in Albania. Int J Lab Hematol 2015; 37(4): 569-74.
  4. Akhtar S, Nasir JA, Hinde A. The prevalence of hepatitis C virus infection in β-thalassemia patients in Pakistan: a systematic review and meta-analysis. BMC PublicHealth 2020; 20(1): 587.
  5. Tarakmeh T, Alaee Karahroudy F, Mamiyanloo yangejeh H, Ghasemi E. Evaluation of the Effect of Self-care Education on the Self-efficacy of Adolescents with Thalassemia Major. Scientific Journal of Nursing, Midwifery and Paramedical Faculty 2018; 4(2): 59-69.
  6. Cheng C, Lee C, Lin C. Clinically significant red blood cell antibodies in chronically transfused patients: a survey of Chinese thalassemia major patients and literature review. Transfusion. 2012; 52(10): 2220-4.
  7. Taher A, Isma'eel H, Cappellini MD. Thalassemia intermedia: revisited. Blood Cells Mol Dis. 2006; 37(1):12-20.
  8. Matteocci A, Pierelli L. Red blood cell alloimmunization in sickle cell disease and in thalassaemia: current status, future perspectives and potential  role  of  molecular  typing.  Vox  sang. 2014; 106(3):197-208.
  9. Reid ME, Hipsky CH, Hue-Roye K, Hoppe C. Genomic analyses of RH alleles to improve transfusion therapy in patients with sickle cell disease. Blood Cells Mol Dis. 2014; 52(4):195-202.
  10. Ye Z, Zhang D, Boral L, Liz C, May J. Comparison of blood group molecular genotyping to traditional serological phenotyping in patients with chronic or recent blood transfusion. J B M. 2016;4(03):1-8.
  11. O'Suoji C, Liem RI, Mack AK, Kingsberry P, Ramsey G, Thompson AA. Alloimmunization in sickle cell anemia in the era of extended red cell typing. Pediatr blood  cancer. 2013; 60(9):1487-91.
  12. Yazdanbakhsh K, Ware RE, Noizat-Pirenne F. Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management. Blood. 2012; 120(3):528-37.
  13. Kutner JM, Mota M, Conti F, Castilho L. Blood genotyping for improved outcomes in chronic transfusion patients: current and future perspectives. International Journal of Clinical Transfusion Medicine. 2014; 2:65-72.
  14. Koçyiğit C, Eliaçık K, Kanık A, Atabay B, Türker M. Frequency of red cell allo-and autoimmunization in patients with transfusion-dependent beta thalassemia and affecting factors. Turk J Pediatr. 2014; 56(5):487-92.
  15. Moghaddam M, Zolfaghari Anaraki S, Shaiegan M, Azarkeivan A. Hyperhemolysis Syndrome in a Patient With B-Thalassemia Due to an Anti-Jka Alloantibody. Journal of Hematology. 2015; 4(3):210-3.
  16. Guelsin GAS, Sell AM, Castilho L, Masaki VL, Melo FC, Hashimoto MN, et al. Benefits of blood group genotyping in multi-transfused patients from the south of Brazil. J clin Lab Anal 2010;24(5): 311-6.
  17. Nadila Haryani O, Jameela S, Chooi Fun L, Noor Fadzilah Z, Raja Zahratul Azma Raja S, Ainoon O, Asral Wirda AA, et al. Importance of extended blood group genotyping in multiply transfused patients. Transfus Apher Sci. 2017; 56(3): 410-16.
  18. Putzulu R, Piccirillo N, Orlando N, Massini G, Maresca M, Scavone F, et al. The role of molecular typing and perfect match transfusion in sickle cell disease and thalassaemia: an innovative transfusion strategy. Transfus Apher Sci. 2017; 56(2):234-37.
  19. Mohamadimaram M,Gharehbaghian A, Abdollahi A, Khansari M. The prevalence of undesired blood group antibodies in thalassemia patients. Sci J Iran Blood Transfus Organ. 2020; 17(2):91-9. [Article in Farsi]
  20. Thedsawad A, Taka O, Wanachiwanawin W. Prevalence and clinical significances of red cell alloimmunization and red cell bound immunoglobulin G in polytransfused patients with thalassemias. Hematology. 2019;24(1):208-14.
  21. Mohamadimaram M, Gharehbaghian A, Baghestani A, Vahidianfar B, Abdollahi A, Razani E, et al. The prevalence of undesired blood group antibodies in Imam Khomeini Hospital Complex patients. Sci J Iran Blood Transfus Organ. 2019; 16(2):82-90. [Article in Farsi]
  22. Darvishi P, Azami M, Sayehmiri K, Sayehmiri F, Goodarzi A, Azarkeivan A, et al. Red blood cell alloimmunization in Iranian beta thalassemia patients: a  systematic  review  and  meta analysis. ISBT Science Series. 2016; 11(3):163-73.
  23. Kiani A, Abdi j, Shirkhani Y, Kashi M. Prevalence of alloimmunization against RBC antigens in thalassemia major patients of Lorestan province in 1383. Sci J Iran Blood Transfus Organ.2006; 3(3): 256-71.
  24. Vaziri M, JavadzadehShahshahani H, Moghaddam M, Taghvaee N. Prevalence and specificities of red cell alloantibodies in transfusion-dependent beta thalassemia patients in Yazd. Iran J Ped Hematol Oncol. 2015; 5(2):93-9.
  25. Sadeghian MH, Keramati MR, Badiei Z, Ravarian M, Ayatollahi H, Rafatpanah H, et al. Alloimmunization among transfusion-dependent thalassemia patients. Asian J Transfus sci. 2009; 3(2):95-8.
  26. Datta SS, Mukherjee S, Talukder B, Bhattacharya P, Mukherjee K. Frequency of red cell alloimmunization and autoimmunization in thalassemia patients: a report from Eastern India. Adv Hematol. 2015;2015.
  27. Hussein E, Eldesooky NH, Rihan A, Kamal A. Predictors of red cell alloimmunization in multitransfused Egyptian patients with β-thalassemia. Arch Pathol Lab Med. 2014;138(5):684-8.
  28. Ameen R, Al-Eyaadi O, Al-Shemmari S, Chowdhury R, Al-Bashir A. Frequency of red blood cell alloantibody in Kuwaiti population. Med Princ Pract. 2005; 14(4):230-4.
  29. El-Beshlawy A, Salama AA, El-Masry MR, El Husseiny NM, Abdelhameed AM. A study of red blood cell alloimmunization and autoimmunization among 200 multitransfused Egyptian β thalassemia patients. Sci Rep. 2020; 10(1): 1-8.
  30. Homeirani F, Keramati MR, Sadeghian MH, Mozafari Z, Moradi Zarmehri A. Red Blood Cells Alloimmunization and Autoimmunization in Multi-transfused Thalassemia Patients in South of Iran. Iran J Ped Hematol  Oncol. 2019; 9(1):40-7.
  31. Tahannejad-Asadi Z, Elahi A, Mohseni AR, Talebi M, Khosravi M, Jalalifar MA. Screening and identifying of erythrocyte alloantibodies in patients with Thalassemia major referred to Ahvaz Shafa hospital. Feyz Journal of Kashan University of Medical Sciences. 2013;17(2):165-72. [Article in Farsi]
  32. Azarkeivan A, Ahmadi MH, Zolfaghari Anaraki S, Shaiegan M, Ferdowsi S, Rezaei N, et al. RBC alloimmunization and double alloantibodies in thalassemic patients. Hematology. 2015;20(4):223-7.
  33. Pazgal I, Yahalom V, Shalev B, Raanani P, Stark P. Alloimmunization and autoimmunization in adult transfusion-dependent thalassemia patients: A report from a comprehensive center in Israel. Ann Hematol. 2020; 99(12) :2731-6.
  34. Zaidi U, Borhany M, Ansari S, Parveen S, Boota S, Shamim I, et al. Red cell alloimmunisation in regularly transfused beta thalassemia patients in Pakistan. Transfus Med. 2015; 25(2):106-10.
  35. Davari K, Soltanpour MS. Study of alloimmunization and autoimmunization in Iranian β-thalassemia major patients. Asian J Ttransfus Sci. 2016; 10(1):88-92.
  36. Keikhaei B, Hirad  Far A, Abolghasemi H, Mousakhani H, Ghanavat M, Moghadam M, et al. Red blood cell alloimmunization in patients with thalassemia major and intermediate in southwest Iran. IJBC. 2013; 6(1):41-6.
 
 
 
Sci J Iran Blood Transfus Organ 2021;18(3): 187-195
 
 
Original Article
 
 
 


Evaluation of alloantibodies in thalassemia patients
referred to Hamadan Besat hospital in 2019
 
Afshari M.1, Amiri F.2, Seyedi M.R.1, Biglari M.1, Jambozorg H.1
 
 
1Student Research Committee, Hamadan University of Medical Science, Hamadan, Iran
2School of Paramedicine, Hamadan University of Medical Sciences, Hamadan, Iran
 
 
Abstract
Background and Objectives
Chronic blood transfusion can cause alloimmunization in patients with thalassemia. Estimating the frequency of alloimmunization in thalassemia patients can lead to the recognition of existing limitations and the development of appropriate strategies to prevent alloimmunization in thalassemia patients. In this study, we evaluated the prevalence of alloimmunization among patients of thalassemia.
 
Materials and Methods
In this cross-sectional and retrospective study, the study population was 92 patients with thalassemia referred to Besat Hospital in Hamadan in 2019. The data of all thalassemia patients was collected by census method and entered into SPSS software version 16. The Data was analyzed using Logestic Regression and significance level by p < 0.05.
 
Results
92 patients including 54 male (58.7% ) and 38 female (41.3%), aged 2-50 years were studied. Among 92 patients, 7 people (7.6%) had positive antibody screening results. The most prevalent detected alloantibodies were anti-c with 6 patients (33.3%), anti-e with 3 patients (16.6%) and anti-JKa with 3 patients (16.6%). The meaningful relation was observed between alloimmunization and hemoglobin concentration (p = 0.006), and alloimmunization and number of blood transfusion (p= 0.009). But there was no significant relation between alloimmunization and age.
 
Conclusions 
According to the results of this study, anti-c, anti-e, and anti-JKa are the most prevalent alloantibodies in the thalassemia patients in Hamadan. This point could be useful to provide suitable matched blood units for thalassemia patients.
 
Key words: Thalassemia, Blood Transfusion, Screening
 
 
 
 
 
 
 
Received:    6 Mar 2021
Accepted: 22 May 2021
 
 

Correspondence: Amiri F., PhD of Hematology & Blood Banking. Assistant Professor in Department of  Medical Laboratory Sciences, School of Para Medicine, Hamadan University of Medical Sciences.
Postal Code: 6517838741, Hamadan, Iran. Tel: (+9881) 38380109; Fax: (+9881) 38381017
E-mail: f.amiri@umsha.ac.ir
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA


XML   Persian Abstract   Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Afshari M, Amiri F, Seyedi M, Biglari M, Jambozorg H. Evaluation of alloantibodies in thalassemia patients referred to Hamadan Besat hospital in 2019. Sci J Iran Blood Transfus Organ. 2021; 18 (3) :187-195
URL: http://bloodjournal.ir/article-1-1400-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 18, Issue 3 (Autumn 2021) Back to browse issues page
فصلنامه پژوهشی خون Scientific Journal of Iran Blood Transfus Organ
The Scientific Journal of Iranian Blood Transfusion Organization - Copyright 2006 by IBTO
Persian site map - English site map - Created in 0.05 seconds with 31 queries by YEKTAWEB 4374